Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer by Kim, Mia et al.
Expression of Foxp3 in Colorectal Cancer but Not in Treg
Cells Correlates with Disease Progression in Patients with
Colorectal Cancer
Mia Kim
1, Tanja Grimmig
2, Martin Grimm
3, Maria Lazariotou
2, Eva Meier
2, Andreas Rosenwald
4,
Igor Tsaur
5, Roman Blaheta
5, Uwe Heemann
6, Christoph-Thomas Germer
1, Ana Maria Waaga-Gasser
2*
.,
Martin Gasser
1.
1Department of Surgery I, University of Wuerzburg, Wuerzburg, Germany, 2Department of Surgery I, Molecular Oncology and Immunology, University of Wuerzburg,
Wuerzburg, Germany, 3Department of Oral and Maxillofacial Plastic Surgery, University of Tuebingen, Tuebingen, Germany, 4Institute of Pathology, University of
Wuerzburg, Wuerzburg, Germany, 5Department of Urology, University of Frankfurt, Frankfurt, Germany, 6Department of Nephrology, University of Munich, Klinikum
rechts der Isar, Munich, Germany
Abstract
Background: Regulatory T cells (Treg) expressing the transcription factor forkhead-box protein P3 (Foxp3) have been
identified to counteract anti-tumor immune responses during tumor progression. Besides, Foxp3 presentation by cancer
cells itself may also allow them to evade from effector T-cell responses, resulting in a survival benefit of the tumor. For
colorectal cancer (CRC) the clinical relevance of Foxp3 has not been evaluated in detail. Therefore the aim of this study was
to study its impact in colorectal cancer (CRC).
Methods and Findings: Gene and protein analysis of tumor tissues from patients with CRC was performed to quantify the
expression of Foxp3 in tumor infiltrating Treg and colon cancer cells. The results were correlated with clinicopathological
parameters and patients overall survival. Serial morphological analysis demonstrated Foxp3 to be expressed in cancer cells.
High Foxp3 expression of the cancer cells was associated with poor prognosis compared to patients with low Foxp3
expression. In contrast, low and high Foxp3 level in tumor infiltrating Treg cells demonstrated no significant differences in
overall patient survival.
Conclusions: Our findings strongly suggest that Foxp3 expression mediated by cancer cells rather than by Treg cells
contribute to disease progression.
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Introduction
The identification of CD4+CD25+ T regulatory cells (Treg) has
been shown to play a crucial role in maintaining immunologic
tolerance. The transcription factor forkhead box protein P3
(Foxp3) has been identified as a key player in Treg function and is
an obligate marker of CD4+CD25+ Treg [1]. Some subclasses of
Treg exert their suppressive influence via the expression of
immunosuppressive cytokines, such as interleukin (IL)-10 and
transforming growth factor (TGF)-b [2,3]. A high density of tumor
infiltrating Foxp3+ Treg in tumor specimen has been associated
with poor outcome in various solid tumors, including ovarian [4],
pancreatic [5], and hepatocellular carcinoma [6]. These findings
suggest a crucial role for Treg in different tumor entities. Thus
targeting Treg may have an important impact on immunother-
apeutic anti-cancer strategies and the clinical outcome of cancer
patients [7].
Treg are suspected of reducing T cell activity but it is not known
whether the presence of Treg may have an impact on the clinical
course and on tumor related survival of patients with CRC. The
prognostic significance of Treg detection in patients with limited
and advanced disease remains still controversial. To date, few
studies have analyzed infiltrating Treg in CRC using Foxp3+
staining. A recent study demonstrated that Treg density was
higher in locally limited than in metastatic disease but was not
associated with the survival of CRC patients [8]. Contrary to the
findings observed in most other human carcinomas, no significant
relation between the absolute number of Foxp3+ infiltrating T
cells and prognosis was observed in several studies with CRC
patients. Furthermore, some other studies suggest that a high
frequency of tumor infiltrating Foxp3+ Treg is associated with
favourable prognosis in CRC [9].
More recent clinical data from lung [10], breast [11,12],
pancreatic [13], hepatocellular [14], and urinary bladder cancer
PLOS ONE | www.plosone.org 1 January 2013 | Volume 8 | Issue 1 | e53630[15] as well as melanoma [16] provided first evidence for a Foxp3
expression also in tumor cells. However, the biological significance
of Foxp3 expression in cancer cells of patients with CRC remains
unknown. In particular, the contribution of Foxp3 expression
related to tumor cells as compared to the expression related to
Treg in clinical CRC has not been evaluated so far. Therefore, the
purpose of this study was to evaluate Foxp3 expression between
tumor infiltrating Treg and cancer cells in patients with CRC at
different stages of the disease as well as to discriminate its
prognostic significance over the long-term.
Results
Detection of CD4, CD25, Foxp3 and immunosuppressive
cytokines IL-10 and TGF-b genes by RT-qPCR and
immunohistochemical analysis
To analyze whether CD4, CD25, Foxp3, IL-10, and TGF-
b expression in CRC may be associated with clinical tumor
progression we investigated tumors of limited disease (UICC I/II)
and advanced disease (UICC III/IV). RT-qPCR analysis showed
significantly increased gene expression of CD4 and CD25 in
limited disease tumors (UICC I/II) compared to tumors of
advanced disease (UICC III/IV). In accordance to this finding,
gene expression of Foxp3 and immunosuppressive cytokines IL-10
and TGF-b was significantly decreased in limited disease tumors
(UICC I/II) compared to those of advanced disease (UICC III/
IV) (Figure 1A).
Next, we examined the expression of Foxp3 and immunosup-
pressive cytokines IL-10 and TGF-b in cancer cells. As shown in
Figure 1B, Foxp3+, IL-10+, and TGF-b+ expressing cancer cells
increased from early to late stages of disease compared to normal
tissue. Foxp3
+ expressing cancer cells were found in 60 out of 65
tumor cases (n=60/65, 92.3%). Additionally, we stained 36 of the
overall 65 cases with a different anti-Foxp3 antibody (clone 2481)
and confirmed the results (data not shown).
Immunohistochemical analysis of CD4+,C D 2 5 +, Foxp3+,
and immunosuppressive cytokines IL-10+ and TGF-b+ in
Treg
We next examined Treg and cancer cells for a detailed
expression analysis of Foxp3, IL-10, and TGF-b by immunohis-
tochemistry. First, we examined the expression of CD4+, CD25+,
Foxp3+, and immunosuppressive cytokines IL-10 and TGF-b in
Treg. As shown in Figure 2A, increased CD4+, CD25+, Foxp3+,
IL-10+, and TGF-b+ expression was observed in limited disease
tumors (UICC I/II) as compared to advanced disease tumors
(UICC III/IV) and normal tissue. Overall, Foxp3+ expressing
Treg in different amounts were found in 61 out of 65 tumors of the
patients (n=61/65, 93.8%). Immunofluorescence double staining
demonstrated that Foxp3+ Treg were of a CD4+ T cell phenotype
(Figure 2B). Only a very small portion of less than 5% of cells was
found to represent a CD8+ T cell subpopulation expressing Foxp3
(data not shown).
Gene and protein analysis of Foxp3 expression in cancer
cells of patients with CRC and in human colon cancer cell
lines by RT-qPCR, immunofluorescence double staining
and flow cytometry
First we demonstrated Foxp3 expression in cancer cells of
patients with CRC using immunofluorescence double staining
(Figure 3). To confirm the Foxp3 expression in tumor cells we
performed RT-qPCR, FACS analysis and immunofluorescence
double staining analyses in different human colon cancer cell lines
(SW480, SW620, and HCT-116). As demonstrated by FACS
3.8% to 6.1% of the cancer cells indeed expressed Foxp3
(Figure 4A and B). Gene analysis by RT-qPCR confirmed its
expression (relative expression in the cell lines ranged between
1.76 and 2.08, Table 1).
Correlation of Foxp3+ cancer cells with the expression of
immunosuppressive cytokines IL-10 and TGF-b
To examine whether the expression of the immunosuppressive
cytokines IL-10 and TGF-b corresponded with the Foxp3+
expressing cancer cells we stratified in two different groups
according to the percentages of expression in the immunohisto-
chemical analysis. Considering Foxp3+ expression in cancer cells
as a continuous variable, regression analysis showed that Foxp3+
cancer cell expression had a weak but significant direct correlation
with the expression of the immunosuppressive cytokines IL-10
(R
2=0.23, p,0.001, n=65; r=0.48) and TGF-b (R
2=0.33,
p,0.001, n=65; r=0.57) (Figure 5A and B).
Immunofluorescence double staining indicated the expression of
the immunosuppressive cytokines IL-10 and TGF-b in Foxp3+
expressing cancer cells (arrows) (Figure 5C and D).
Correlation of Foxp3+ Treg with Foxp3+ cancer cells
To examine whether Foxp3+ Treg expression corresponded
with the Foxp3+ cancer cell expression, we stratified two different
groups according to percentages expression of immunohistochem-
ical analysis. Considering the Foxp3+ cancer cell expression as
Figure 1. Gene and protein expression analysis of CD4, CD25,
Foxp3, IL-10, and TGF-b from patients with CRC (n=65) by RT-
qPCR and immunohistochemical analysis of cancer cells in
early (UICC I/II) and late stage (UICC III/IV) of the disease. (A)
Significantly increased gene expression of CD4 and CD25 at stage UICC
I/II compared to tumors at stage UICC III/IV. Gene expression of Foxp3,
IL-10, and TGF-b was significantly decreased at stage I/II as compared
with those at UICC III/IV. The normalization was performed with normal
tissue. The relative quantification value, fold difference, is expressed as
2
2DDCt.* p ,0.001. (B) Foxp3+, IL-10+, and TGF-b+ expressing cancer
cells increased from UICC I/II to UICC III/IV compared to normal tissue.
The result of the staining was expressed in percentages (%) positivity.
All values were expressed as mean 6 SD; all pairwise tests (Tukey) result
in p,0.001 with exception of control vs. UICC I/II in Foxp3
+ (p,0.050).
doi:10.1371/journal.pone.0053630.g001
Foxp3 Expression and CRC Disease Progression
PLOS ONE | www.plosone.org 2 January 2013 | Volume 8 | Issue 1 | e53630Figure 2. Immunohistochemical analysis of CD4+, CD25+, Foxp3+, IL-10+, and TGF-b+ expression in Treg from patients with CRC
(n=65) in early (UICC I/II) and late stage (UICC III/IV) of the disease. (A) Increased CD4+, CD25+, Foxp3+, IL-10+, and TGF-b+ expression at
stage UICC I/II as compared with those at UICC III/IV. The result of the staining was expressed in percentages (%) positivity. All values were expressed
as mean 6 SD. All pairwise tests result in p,0.001 with three exceptions: Foxp3
+, control vs. UICC III/IV, p=0.091; IL-10
+, UICC I/II vs. UICC III/IV,
p=0.021; TGF-ß
+, UICC I/II vs. UICC III/IV, p=0.020. (B) Representative example of an immunofluorescence double staining of Foxp3+ and CD4+ in
Treg. Foxp3 expression was mainly observed on CD4+ Treg (arrow) (6400 magnification). FITC, green Fluoresceinisothiocyanate, Cy3,
indocarbocyanin red, and DAPI 49,6-Diamidino-2- phenylindoldihydrochlorid blue – nuclear counterstaining.
doi:10.1371/journal.pone.0053630.g002
Figure 3. Immunofluorescence double staining of Foxp3 and EPCAM in cancer cells from patients with CRC. Representative example of
an immunofluorescence double staining, showing Foxp3 expression and EPCAM costaining in cancer cells of patients with CRC (6100 magnification
above; 6400 magnification below). FITC, green Fluoresceinisothiocyanate, Cy3, indocarbocyanin red and DAPI 49,6-Diamidino-2- phenylindoldihy-
drochlorid blue – nuclear counterstaining.
doi:10.1371/journal.pone.0053630.g003
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cancer cell expression had a weak but significant inverse
correlation with the Foxp3+ Treg expression (R
2=0.17,
p=0.01, n=65; r=20.41) (Figure 6A). Immunohistochemistry
showed increased Foxp3+ Treg expression in Foxp3 negative
cancer stromal tissue (arrow) (Figure 6B). In contrast, there was
no or negligible Foxp3+ Treg expression found in Foxp3 positive
cancer tissue (arrow) (Figure 6C).
Overall survival
Multivariate Cox regression analysis was performed stepwise
including age, gender, primary tumor (colon or rectum), UICC (I/
II or III/IV), depth of tumor invasion (T category 1/2 or 3/4),
differentiation (1/2 or 3/4), lymph node metastasis (N category),
Foxp3 (%), Treg (%), TGF-ß (%), and IL-10 (%). The stepwise
procedure kept in the model the N category and Foxp3 expression
in colon cancer cells as prognostic parameters (Chi-quadrat
statistics, p,0.01, Table 2).
Univariate results using Kaplan-Meier
The identified prognostic factors from Cox regression model are
presented in Figures 7A and C. The mean value of Foxp3+ cancer
cell expression by immunohistochemical analysis for all studied
tissue samples of the 65 tumors was determined at 16%. Among
patients with CRC, those with high Foxp3+ cancer cell expression
(.16%) had a poorer prognosis than those with low Foxp3+
expression levels (,16%) (p,0.001, Log-Rank test) (Figure 7A
and Table 3).
Considering immunohistochemical analysis of the samples from
the 65 tissue samples for Foxp3+ Treg expression the mean value
was calculated at 12%. There was no significant difference in the
overall survival comparing patients with low and high Foxp3+
Figure 4. Protein expression of Foxp3 in colon cancer cell lines by flow cytometry and immunofluorecence double staining
analysis. (A) Flow cytometry assay of Foxp3 expression in SW480, SW620, and HCT-116 colon cancer cell lines compared to isotype control. 3.8% to
6.1% of colon cancer cells express Foxp3; PE: phycoerythrin; FS: forward scatter linear. (B) Representative examples of immunofluorescence double
staining of Foxp3+ expression in SW480, SW620, and HCT-116 cancer cells. Cy3, indocarbocyanin red and DAPI 49,6-Diamidino-2-
phenylindoldihydrochlorid blue – nuclear counterstaining (6400 magnification).
doi:10.1371/journal.pone.0053630.g004
Table 1. Quantitative Real Time PCR analysis of Foxp3
expression in colon cancer cell lines.
DCt Relative expression
SW480 15.15 1.76
SW620 20.54 2.08
HCT-116 19.09 1.95
Foxp3 is expressed in the human colon cancer cell lines SW480, SW620, and
HCT-116 (n=5).
doi:10.1371/journal.pone.0053630.t001
Foxp3 Expression and CRC Disease Progression
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test) (Figure 7B and Table 3).
In patients without lymph node metastasis were significant
differences in overall survival compared to patients with lymph
node metastasis (p,0.001, Log-Rank test) (Figure 7C).
Other parameters such as TGF-ß, IL-10, UICC, and T
category showed additionally significant differences in overall
survival for the corresponding lower expression and grading,
respectively (p,0.001, Log-Rank tests).
Age, gender, primary tumor, and histological differentiation
were not associated with prognosis in univariate analysis.
Discussion
The current study provides for the first time evidence of
a significantly increased tumor-related expression of the transcrip-
tion factor Foxp3 in colorectal cancer cells that is associated with
adverse prognosis. Detailed protein and gene analysis was used to
study its expression profiles in each tumor tissue of the patients.
Based on more recently described clinical findings of a Foxp3
expression in cancer cells of tumors like lung, hepatocellular, and
urinary bladder cancer as well as melanoma we suggested that
elevated Foxp3 expression levels were not necessarily associated to
Treg alone but also to cancer cells [10,14,15]. Expression of Foxp3
by cancer cells would enable them to downregulate effector T cell
responses directed against the tumor. This would give clinical
evidence for an effective mechanism of a direct tumor-derived
evasion from immunological destruction in CRC. By discriminat-
ing Foxp3 expression of cancer cells from infiltrating Treg and
correlating with overall survival over a long-term follow-up we
provide new insights in its prognostic significance.
In accordance with previous studies in various malignant
diseases we found significantly higher numbers of infiltrating Treg
(CD4+CD25+Foxp3+) in all CRC samples compared with normal
colon tissues [4–6,17–20]. However, the association of Foxp3
expression in Treg and its impact on overall survival remains
controversial. Ambiguous data suggest that tumor infiltration by
Foxp3+ Treg is not always associated with a poor prognosis, but,
on the contrary, can be associated with an improved prognosis in
some cancer types like in CRC [8,9,21,22]. Moreover, no
significant relation was observed between the absolute number
of Foxp3+ Treg and prognosis in CRC [23,24]. Improved survival
and the potentially protective role of Treg might be explained by
their capacity of reducing the development of an aggressive and
cytotoxic, potentially proliferogenic cytokine milieu, which is the
basis for an inflammation-driven progress of malignant diseases
[25,26].
Experimental studies in mice showed that CD4+CD25+Treg do
not only play a central role in the maintenance of immunological
tolerance but that Treg are also potent inhibitors of antitumor
immune responses [27,28]. Previous studies have examined the
suppressive capacities of CD8+CD25+Foxp3+ T cells in colorectal
cancer tissues [29]. In CRC specimens the absolute number of
CD8+CD25+Foxp3+ T cells were low (,5%). In addition, these
Figure 5. Correlation of Foxp3+ cancer cell expression with immunosuppressive cytokines IL-10+ and TGF-b+ and immunofluo-
rescence double staining. (A/B) Significant correlation of Foxp3+ cancer cell expression with the expression of IL-10 (A) and TGF-b (B). Regression
analysis; R
2, coefficient of determination. (C/D) Representative example of an immunofluorescence double staining of IL-10+ (C) and TGF-b+ (D)i n
Foxp3+ cancer cells (arrows). FITC green Fluoresceinisothiocyanate, Cy3 red and DAPI 49,6-Diamidino-2- phenylindoldihydrochlorid blue – nuclear
counterstaining.
doi:10.1371/journal.pone.0053630.g005
Foxp3 Expression and CRC Disease Progression
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CRC specimens; however their clinical relevance remains un-
known [29]. Several groups observed Foxp3 expression by various
cancer types and its potential role on immune surveillance by
producing immunosuppressive cytokines such as IL-10 and TGF-
b [30].
Finally, we analyzed the overall survival of patients with low or
high Foxp3+ Treg infiltration in the tumor in comparison to the
survival of patients with low or high Foxp3 expression of their
cancer cells. Those patients with high Foxp3+ expression profile in
cancer cells were associated with a poorer prognosis than patients
with low expression profile of Foxp3+ in their cancer cells. This
correlation of high Foxp3 expression pattern with poor prognosis
was not observed for infiltrating Treg in the tumor. Cancer cells
expression of Foxp3 followed by secretion of immunosuppressive
cytokines into the microenvironment of the tumor tissue may give
the tumor a powerful tool to circumvent immunological de-
struction. Interestingly, an inverse correlation between the number
of Foxp3+ Treg and the level of Foxp3+ cancer cells was observed
in our patients with CRC suggesting an anti-proliferative effect of
TGF-b on Treg.
In conclusion, despite the fact that the sample size in this cohort
is small to draw definitive conclusions, our study shows for this first
time that high Foxp3 expression in cancer cells is associated with
a dismal prognosis in CRC. Multivariate Cox regression analysis
demonstrated lymph node metastasis (N category) and Foxp3
expression in colon cancer cells as significant prognostic param-
eters of survival in human CRC.
Materials and Methods
Ethics statement
Ethical approval for this research was obtained from the
Human Research Ethics Committee of the University of
Wuerzburg. All patients providing tumor tissue as well as normal
colon tissue samples signed a consent form prior to surgical
removal of the intestinal cancer to allow for this research to be
undertaken.
Patients and controls
Sixty-five patients with histologically confirmed CRC cancer
undergoing curative surgical resection in our department between
01/2001 and 06/2004 were included in the study. The histological
stage of the tumor was determined according to the Union
Internationale Contre le Cancer (UICC)-TNM staging system
[31]. Tumors were evaluated for location, stage, and differenti-
ation grade. Data concerning age, gender, level of wall infiltration,
and lymph node metastasis were collected in a database. Regular
medical visits of the patients after curative therapy were performed
at intervals according to the governmental guidelines for tumor
patients. Patients, who underwent any neoadjuvant treatment or
R1 resection were excluded from analysis. Tumor tissue samples as
well as normal colon tissue samples from the patients were frozen
instantly in liquid nitrogen, and stored at 280uC until analyzed.
Normal colon tissues from healthy individuals served as controls
(n=10). Immunohistochemical analysis confirmed that no ana-
lyzed tumor from the patient cohort expressed hMLH1 and
hMSH2 indicative for microsatellite instability (positive mismatch
repair [MMR] status). The mucinous phenotype of CRC could be
associated with false positive subcellular reactions by immunohis-
tochemistry and was therefore excluded from our study. Clinical
characteristics of the study population are summarized in Table 3.
All patients completed at least a 60 months follow-up after
resection.
Cell culture
The human colon cancer cell lines SW620, SW480, and HCT-
116 were obtained from ATCC (Manassas, VA) and cells were
cultured at 37uCi n5 %C O 2 using RPMI 1640 Medium (Life
Figure 6. Correlation of Foxp3+ Treg with Foxp3+ cancer cell
expression and immunohistochemical analysis of Foxp3+ Treg
and Foxp3+ cancer cells. (A) Significant inverse correlation of
Foxp3+ cancer cell expression with the Foxp3 Treg expression.
Regression analysis; R
2, coefficient of determination. (B) Increased
numbers of Foxp3+ Treg in Foxp3 negative cancer tissue (arrow). (C)
Only occasionally or no Foxp3+ Treg in Foxp3 positive cancer tissue
(arrow). DAB brown color, Haemalaun blue color – nuclear counter-
staining. Representative example demonstrates area of magnifications
x100 (left) and x200 (right).
doi:10.1371/journal.pone.0053630.g006
Table 2. Multivariate analysis of prognostic factors of the study population.
Unfavorable factor Hazard ratio (HR) 95% CI of HR x
2 p-values
Lymph nodes metastasis Positive 8.97 2.28 to 35.31 0.002
Foxp3+ cancer cells High 1.09 1.02 to 1.14 0.006
Lymph node metastasis (N category) and Foxp3+ were found to be prognostic parameters of survival (p,0.01, Chi-Quadrat).
doi:10.1371/journal.pone.0053630.t002
Foxp3 Expression and CRC Disease Progression
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(v/v) fetal bovine serum (Life Technologies, GIBCO, Carlsbad,
CA), 1% (v/v) L-glutamine (Biochrom AG, Berlin, Germany) and
1% (v/v) penicillin/streptomycin (Biochrom AG, Berlin, Ger-
many).
Flow cytometry analysis (FACS)
Cancer cells from the human colon cancer cell lines SW620,
SW480, and HCT-116 were harvested at an exponential growth
phase using enzyme free cell dissociation solution (Merck
Millipore, Billerica, MA) and analyzed for Foxp3 expression.
After washing with dPBS (Life Technologies, GIBCO, Carlsbad,
CA) twice, 5610
5 cells were treated with Foxp3 staining buffer kit
(Miltenyi Biotec, Bergisch Gladbach, Germany) according to the
manufacturer’s instructions and incubated with PE-conjugated
antibody Foxp3 or IgG1 (Miltenyi Biotec, Bergisch Gladbach,
Germany) for 30 min at 4uC in the dark. The fluorescence of
Foxp3 was measured and analyzed with a FACS flow cytometer
(Coulter EPICS XL, Beckman Coulter, Brea, USA).
Immunohistochemical and immunofluorescent staining
CD4 and CD25 antibodies were provided by Dako (Hamburg,
Germany). Two different Foxp3 antibody clones (ab22510 mouse
monoclonal and ab2481 goat polyclonal) were purchased from
Abcam (Cambridge, UK), TGF-b antibody was provided by
Serotec (Duesseldorf, Germany), and IL-10 antibody by R&D
Systems (Wiesbaden-Nordenstadt, Germany). Isotype control
antibodies were purchased from eBioscience (San Diego, USA).
Secondary antibodies used for immunofluorescence double
staining and immunohistochemistry were provided by Jackson
ImmunoResearch Laboratories Inc. (Suffolk, England). Secondary
EPCAM and CD4 antibodies were FITC-conjugated AffiniPure
Donkey anti-goat IgG and secondary antibody of Foxp3, IL-10,
and TGF-b was Cy3-conjugated AffiniPure Donkey anti-mouse
IgG at a 1:200 dilution (Jackson ImmunoResearch).
For cytospin preparations colorectal carcinoma cells from the
patients with CRC were cultured in short-term primary cultures
and established human colon cancer cell lines were harvested at an
exponential growth phase using enzyme free cell dissociation
solution (Merck Millipore, Billerica, MA). After washing with
dPBS (Life Technologies, GIBCO, Carlsbad, CA) twice, cells were
adjusted to a concentration of 2610
5 cells/ml. Cytospins were
performed with 50 ml cell suspension at 550 rpm for 1 min in
a Cytospin4 Cytocentrifuge (Thermo Fisher Scientific, Waltham,
MA).
The staining of CD4, CD25, Foxp3, TGF-b, and IL-10 was
performed on serial cryostat sections of the 65 snap-frozen CRC
specimens in early-stage tumors (UICC I/II) and late-stage tumors
(UICC III/IV) with neighbouring normal colon tissue and 10
normal colon specimens. All tumors stained positive for cytoker-
atin-20 (CK-20) (Dako, Hamburg, Germany) and negative for
cytokeratin-7 (CK-7) (Dako), a pattern characteristic for colonic
adenocarcinoma [32]. First we assessed H.E. sections from each
tumor tissue to differentiate between cancer cell areas, stromal
Figure 7. Overall survival of cancer patients with Foxp3+ cancer cell expression in their CRCs compared with the overall survival of
those with infiltrated Foxp3+ Treg in their tumors. (A) Patients with high Foxp3+ cancer cell expression (.16%, as mean cut-off) had a poorer
prognosis than those with low Foxp3+ cancer cell expression profiles (,16%; mean cut-off: 16%), (p,0.001, Log-Rank test). (B) No significant
difference in the overall survival comparing patients with low and high Foxp3+ Treg expression profiles (mean cut-off: 12%), (p=0.202, Log-Rank
test). (C) Patients with lymph node metastasis had a poorer prognosis than those without lymph node metastasis (p,0.001, Log-Rank test). The times
of the censored data are indicated by short vertical lines.
doi:10.1371/journal.pone.0053630.g007
Foxp3 Expression and CRC Disease Progression
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CD25, Foxp3, TGF-b, and IL-10 in following serial sections. For
Foxp3 expression cytoplasmic, perinuclear cytoplasmic, and
nuclear staining pattern were differentially determined [30]. Serial
cryostat sections (5 mm) were incubated with the primary antibody
or control antibody and with secondary FITC-conjugated
(Fluoresceinisothiocyanate) antibody. Then the slides were sub-
sequently incubated with the second primary antibody followed by
incubation with secondary Cy3-conjugated antibody. Slides were
counterstained with DAPI (49,6-Diamidino-2-phenylindoldihydro-
chlorid) (Sigma-Aldrich, Steinheim, Germany) and covered with
Polyvinyl-alcohol mounting medium (DABCO, Sigma-Aldrich)
and analyzed using a Zeiss camera (Oberkochen, Germany).
For immunohistochemistry, the pre-treatment (fixation) of the
slides was the same as described for immunofluorescence. After
incubation with the primary antibody, we used a horseradish
peroxidase (HRP)-conjugated AffiniPure Donkey anti-mouse or
a Donkey anti-goat IgG (Jackson ImmunoResearch). Slides were
subsequently incubated in DAB (3,39-diaminobenzidine) (Bio-
genex, San Ramon, USA), counterstained with Haemalaun and
mounted with Glycergel (Dako, Hamburg, Germany). The
quantification of each immunoenzymatic staining of tumor cells
out of 65 individual tumor tissues in six individual magnified fields
(6400 magnification) for each staining sample was scored by cell
counting performed by two independent investigators blinded for
the underlying disease. The magnified fields were representative
for the whole tumor section. The result of the staining was
expressed in percentages (%) positivity. All values were expressed
as mean 6 SD.
Real-time quantitative reverse transcription-PCR analysis
To analyze gene expression of CD4, CD25, Foxp3, TGF-b, and
IL-10 by RT-qPCR, we extracted total cellular RNA using the
RNeasy Minikit from Qiagen (Hilden, Germany). Areas of interest
(only epithelial regions) for each tissue section were manually
microdissected using a scalpel blade. Equal amounts of tissue areas
were assessed (261.5 cm
2 surface area per section, thickness of
10 mm). RNA extraction of patient samples and established
Table 3. Clinicopathological characteristics of the study population and discrimination of Foxp3 expression profiles.
Total Foxp3 (cancer cells) Foxp3 (Treg)
Low High Test Low High Test
Cases (n) 65 (100%) 31 (100%) 34 (100%) 38 (100%) 27 (100%)
Age (y; mean 6 sd) 64.065.8 63.965.7 64.265.9 n.s. 64.266.0 63.865.6 n.s.
Gender
Male 37 (57%) 18 (58%) 19 (56%) n.s. 21 (55%) 16 (59%) n.s.
Female 28 (43%) 13 (42%) 15 (44%) 17 (45%) 11 (41%)
Primary tumor
Colon 26 (40%) 12 (39%) 14 (41%) n.s. 16 (42%) 10 (37%) n.s.
Rectum 39 (60%) 19 (61%) 20 (59%) 22 (58%) 17 (63%)
Differentiation
G1 12 (18%) 7 (22%) 5 (15%) n.s. 4 (11%) 8 (30%) n.s.
G2 31 (48%) 16 (52%) 15 (44%) 21 (55%) 10 (37%)
G3/4 22 (34%) 8 (26%) 14 (41%) 13 (34%) 9 (33%)
Depth of invasion
pT1 14 (22%) 10 (32%) 4 (12%) ,0.001 8 (21%) 6 (22%) n.s.
pT2 23 (35%) 14 (45%) 9 (27%) 13 (34%) 10 (37%)
pT3 17 (26%) 7 (23%) 10 (29%) 10 (26%) 7 (26%)
pT4 11 (17%) - 11 (32%) 7 (19%) 4 (15%)
Lymph node metastasis
pN0 31 (48%) 25 (81%) 6 (18%) ,0.001 14 (37%) 17 (63%) 0.038
pN1–3 34 (52%) 6 (19%) 28 (82%) 24 (63%) 10 (37%)
UICC stage
UICC I 15 (23%) 13 (42%) 2 (6%) ,0.001 8 (21%) 7 (26%) n.s.
UICC II 19 (29%) 16 (52%) 3 (9%) 7 (18%) 12 (45%)
UICC III 22 (34%) 1 (3%) 21(62%) 16 (43%) 6 (22%)
UICC IV 9 (14%) 1 (3%) 8 (23%) 7 (18%) 2 (7%)
Mean OS (m) 35 27 38 35
Median OS (m) n.a. 20 47 n.a.
Log-Rank test p,0.001 p=0.204
Patients with CRC and with high Foxp3+ cancer cell expression ($16%; mean cut-off 16%) had a poorer prognosis than those with low Foxp3+ cancer cell expression
(,16%). No significant difference in the overall survival comparing patients with low and high Foxp3+ Treg expression (mean cut-off: 12%). Y, years; G, grading; UICC,
International Union against Cancer; R, residual tumor; OS, overall survival; m, months; n.s., not significant; n.a., not applicable.
doi:10.1371/journal.pone.0053630.t003
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manufacturer’s instructions. Primer sets were obtained from
Qiagen, 18S RNA primer pairs (forward: TCA AGA ACG
AAA GTC GGA GGT TCG, reverse: TTA TTG CTC AAT
CTC GGG TGG CTG) were designed by Biomers (Ulm,
Germany). Matched human colon cDNA was purchased from
Pharmingen (Heidelberg, Germany) as control and was standard-
ized to baseline. The housekeeping genes Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), ß-actin, and 18S RNA
[33] were used for relative quantification and cDNA quality
control. All PCR reactions were carried out with a DNA Engine
Opticon 2 System (MJ Research, Biozym, Oldendorf, Germany).
The relative quantification value, fold difference, was expressed as
2
2DDCt. For the analysis in colon cancer cell lines expression is
indicated in mean value, DCt and relative expression (Foxp3/
Housekeeping genes).
Statistical analysis
Statistical analysis was performed using SAS 9.2. Overall
survival was defined as the time period between randomisation
and death of any cause. Patients, who were lost to follow-up were
censored at the date of last contact. The overall survival was
evaluated by means of PROC PHREG (Cox Proportional
Hazards Model). The parameters of prognostic potential, identi-
fied in a stepwise procedure, have been further investigated by
Kaplan-Meier method (PROC LIFETEST). For univariate
analysis mean cut-off value for either high or low expression was
set at 12% for Foxp3 in tumor infiltrating Treg and 16% for
Foxp3 in cancer cells. Univariate analysis of significance for Foxp3
expression of tumor infiltrating Treg and cancer cell expression
differences in survival curves were evaluated by Log-rank test. In
the same way survival curves were compared for N and T
categories as well as primary tumor.
Two independent groups of patients were analyzed using
Student’s t test (Satterthwaite). More than two groups were
analyzed applying PROC GLM (analysis of variances) with post-
hoc testing (Tukey). Frequency distributions were compared using
kxm tables (Chi-quadrat). Pearson’s correlation coefficient was
used to describe and to test bivariate correlations. A p-value of less
than 0.05 was considered statistically significant.
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